|
|
Volumn 2, Issue 3, 2001, Pages 104-112
|
|
Flat or monotonic pricing of pharmaceuticals: Practice and consequences
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMLODIPINE BESYLATE;
ATENOLOL;
BETAXOLOL;
BISOPROLOL FUMARATE;
CANDESARTAN HEXETIL;
CAPTOPRIL;
CARVEDILOL;
CILAZAPRIL;
DILTIAZEM;
DRUG;
ENALAPRIL MALEATE;
EPROSARTAN;
FELODIPINE;
FOSINOPRIL;
GENERIC DRUG;
IRBESARTAN;
LABETALOL;
LISINOPRIL;
LOSARTAN POTASSIUM;
METOPROLOL TARTRATE;
MOEXIPRIL;
NON PRESCRIPTION DRUG;
PINDOLOL;
PROPRANOLOL;
QUINAPRIL;
RAMIPRIL;
SOTALOL;
TRANDOLAPRIL;
UNINDEXED DRUG;
VALSARTAN;
ARTICLE;
COMPETITION;
CONSUMER;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DRUG CLASSIFICATION;
DRUG COST;
DRUG FORMULATION;
DRUG MARKETING;
DRUG POTENCY;
ECONOMIC ASPECT;
HEALTH CARE;
HUMAN;
PATENT;
PATIENT SATISFACTION;
PRESCRIPTION;
PRIORITY JOURNAL;
PROSPECTIVE PRICING;
|
|
EID: 0034789833
PISSN: 14393972
EISSN: None
Source Type: Journal
DOI: 10.1007/pl00012222 Document Type: Article |
|
Times cited : (8)
|
|
References (8)
|
